BG-C9074

DRUG2 trials

Sponsors

BeOne Medicines

Conditions

Advanced Solid TumorEpithelial Ovarian CancerFallopian Tube CancerPrimary Peritoneal Cancer

Phase 1

Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors

RecruitingNCT06233942

BeOne MedicinesAdvanced Solid Tumor

Start: 2024-04-12End: 2028-05-15Target: 308Updated: 2026-09-16

Phase 3

Efficacy and Safety of BG-C9074 With Bevacizumab Compared With Bevacizumab in Adults With Ovarian, Fallopian Tube, or Primary Peritoneal Cancers

Not yet recruitingNCT07811271

BeOne MedicinesEpithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer

Start: 2026-10-01End: 2033-03-31Target: 600Updated: 2026-09-10

Related Papers

Consideration of adjusted ideal body weight dosing in BG-C9074 (B7-H4–targeting ADC) from pharmacokinetics, efficacy, and safety perspectives.

Journal of Clinical Oncology2026-05-27

First-in-human study of BG-C9074 (B7-H4–targeting ADC) in advanced solid tumors: Dose escalation and safety expansion.

Journal of Clinical Oncology2026-05-27

First-in-human study of BG-C9074, a B7-H4-targeting ADC in patients with advanced solid tumors: Preliminary results of the dose-escalation phase.

Journal of Clinical Oncology2025-05-281 citations